Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Januari 24, 2025
PERSBERICHT GEREGLEMENTEERDE INFORMATIE 24 januari 2025, 19:30 CET Conversie van EUR 0,53 miljoen onder de Sensinnovat 2020 lening, EUR 1,28 miljoen onder de 2024 converteerbare lening met verschillende aandeelhouders, en EUR 2,68 miljoen onder de Kreos 2022 lening in eigen vermogen, vermindert de nettoschuld met EUR 4,50 miljoen Gent, België, 24 januari 2025 – Sequana...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN